Space Pharma Market Thrives Amidst Mega-IPO Frenzy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 09 2026
0mins
Source: CNBC
- Market Potential: Morgan Stanley predicts that the space economy could exceed $1 trillion by 2040, with the pharmaceutical sector likely to experience the most immediate disruption, prompting a growing number of companies to explore drug development in low Earth orbit.
- Technological Breakthroughs: Redwire's SpaceMD has successfully flown 54 PIL-BOX units and tested 37 drug compounds, leveraging the zero-gravity environment to produce more uniform drug crystals, thereby enhancing drug absorbability and stability.
- Strengthened Partnerships: SpaceMD's collaboration with pharmaceutical giants like Eli Lilly and Bristol Myers Squibb showcases the potential of new crystal forms, driving the development of new drug candidates and highlighting the commercial viability of space pharmaceuticals.
- Future Directions: As the International Space Station approaches retirement, SpaceMD is establishing relationships with commercial low Earth orbit destination providers, aiming for increased flight frequency and the development of fixed infrastructure to support the long-term growth of space pharmaceuticals.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1112.000
Low
950.00
Averages
1192
High
1500
Current: 1112.000
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vertex and Eli Lilly's Market Competition in Pain Management
- Vertex Drug Approval: Vertex Pharmaceuticals' Journavx has become the first FDA-approved non-opioid pain signal inhibitor, marking a significant breakthrough in acute pain management, with expected sales growth over the coming years that will help reduce reliance on cystic fibrosis drugs.
- Eli Lilly Acquisitions: Last year, Eli Lilly acquired SiteOne Therapeutics for up to $1 billion, gaining the non-opioid chronic pain treatment STC-004, and recently announced the acquisition of 4E Therapeutics, further enhancing its competitive position in the pain management market.
- Market Potential: Vertex estimates that there are 80 million acute pain patients in North America and Europe, providing both Vertex and Eli Lilly opportunities to profit in this market; although Vertex currently leads, Eli Lilly's R&D progress could shift the competitive landscape.
- Strong Financial Performance: Despite Vertex's underperformance over the past 12 months, it expects to generate at least $500 million in revenue this year from Journavx and gene-editing drug Casgevy, indicating potential in new drug launches, while Eli Lilly is also viewed as a strong investment due to its robust pipeline and profitability.
See More
Vertex and Eli Lilly Compete in Non-Opioid Pain Management Market
- Intensifying Market Competition: Vertex Pharmaceuticals leads the non-opioid pain management market with its FDA-approved Journavx, the first oral non-opioid pain signal inhibitor, which, despite currently low revenue, is expected to see significant sales growth in the coming years and may expand into diabetic peripheral neuropathy (DPN) treatment.
- Acquisition Strategy: Eli Lilly is actively entering the non-opioid pain management space through acquisitions, including SiteOne Therapeutics for up to $1 billion and 4E Therapeutics, whose lead asset 4ET1103 demonstrated a robust safety profile in phase 1 studies, indicating Lilly's potential in this market.
- Vast Market Opportunity: Vertex estimates that there are 80 million patients suffering from acute pain in North America and Europe, with several million more in niche markets like DPN, providing significant market opportunities for both Vertex and Eli Lilly; while Vertex currently holds the lead, Lilly could dominate if its products demonstrate superior efficacy.
- Strong Financial Performance: Although Vertex has lagged broader equities over the past 12 months, its dominance in the cystic fibrosis market ensures solid financial results, with expectations of at least $500 million in revenue this year from Journavx and gene editing drug Casgevy, highlighting the company's potential in new product launches.
See More
Vertex and Eli Lilly's Market Competition in Pain Management
- Market Leadership: Vertex Pharmaceuticals holds a monopoly in the cystic fibrosis (CF) drug market, while Eli Lilly excels in anti-obesity medications and diabetes care, although both companies are actively seeking to reduce their reliance on their core markets.
- Non-Opioid Drug Innovation: Vertex's Journavx became the first oral non-opioid pain signal inhibitor approved by the FDA, and while it has not generated significant revenue yet, sales are expected to ramp up over the next few years, helping the company decrease its dependence on CF products.
- Acquisition Strategy: Eli Lilly acquired SiteOne Therapeutics last year for up to $1 billion, securing the key asset STC-004, a non-opioid treatment for chronic pain, and recently announced the acquisition of 4E Therapeutics, further expanding its footprint in the non-opioid pain treatment space.
- Market Opportunity: Vertex estimates that there are 80 million patients suffering from acute pain in North America and Europe, providing both Vertex and Eli Lilly with significant profit potential in this market; despite Vertex's first-mover advantage, Eli Lilly could still dominate if its candidates demonstrate superior efficacy.
See More
ARK Invest Increases Stake in Tesla and Snowflake While Reducing Roku Holdings
- Increased Tesla Holdings: On June 18, ARK Invest acquired approximately 44,000 shares of Tesla valued at about $17.6 million, reflecting ongoing confidence in the electric vehicle market despite market fluctuations.
- Acquisition of Snowflake: The firm also purchased around 149,700 shares of Snowflake for approximately $34.8 million, indicating a bullish outlook on cloud computing and data analytics, aiming to capitalize on future growth opportunities.
- Reduced Roku Exposure: ARK Invest sold about 561,800 shares of Roku valued at approximately $77.6 million, reducing its investment in the streaming platform, which reflects a reassessment of technology stocks and portfolio adjustments.
- Healthcare Investment: Additionally, ARK increased its stake in Eli Lilly by nearly 2,400 shares worth about $2.7 million, demonstrating a focus on the healthcare sector to diversify its portfolio amid market uncertainties.
See More
Eli Lilly and Twist Leverage AI to Accelerate Drug Development
- AI Innovation at Eli Lilly: Eli Lilly is collaborating with OpenAI to accelerate drug discovery and has established an AI co-innovation lab with Nvidia, aiming to identify promising molecules faster than traditional methods, which is expected to enhance its competitive edge in drug development.
- Strong Financial Performance: In Q1 2026, Eli Lilly reported a 56% revenue increase to $19.8 billion and a 168% surge in net income to $7.4 billion, demonstrating the company's ability to achieve high growth efficiency despite its large scale, further solidifying its market position.
- Growth Potential for Twist: Twist Bioscience's revenue rose 19% to $110.7 million in Q2 of fiscal 2026, marking 13 consecutive quarters of growth; however, its net loss widened to $44 million, yet the partnership with Amazon provides significant momentum for future drug development.
- Market Outlook Analysis: Both companies showcase distinct approaches in AI-driven drug development, with Eli Lilly focusing on innovation in established drugs while Twist seeks higher-risk returns in synthetic DNA, reflecting the broad potential of AI in the pharmaceutical industry.
See More
Eli Lilly and Twist Bioscience: AI in Drug Development
- AI Innovation at Eli Lilly: Eli Lilly collaborates with OpenAI for drug discovery and establishes an AI co-innovation lab with Nvidia, aiming to accelerate drug development and enhance its position in the competitive pharmaceutical market.
- Strong Financial Performance: In Q1 2026, Eli Lilly reported a 56% revenue increase to $19.8 billion and a 168% surge in net income to $7.4 billion, indicating improved operational efficiency and promising future growth potential despite its large scale.
- Market Dynamics for Twist Bioscience: Twist Bioscience's revenue rose 19% to $110.7 million in Q2 2026, marking 13 consecutive quarters of growth, although net losses widened to $44 million, highlighting challenges faced during expansion.
- Partnership with Amazon: Twist Bioscience has become a key lab in Amazon's Bio Discovery platform, leveraging AI to design drugs and collaborate with real-world partners, which is expected to create new business growth opportunities and enhance its market competitiveness.
See More
Vertex and Eli Lilly's Market Competition in Pain Management
- Vertex Drug Approval: Vertex Pharmaceuticals' Journavx has become the first FDA-approved non-opioid pain signal inhibitor, marking a significant breakthrough in acute pain management, with expected sales growth over the coming years that will help reduce reliance on cystic fibrosis drugs.
- Eli Lilly Acquisitions: Last year, Eli Lilly acquired SiteOne Therapeutics for up to $1 billion, gaining the non-opioid chronic pain treatment STC-004, and recently announced the acquisition of 4E Therapeutics, further enhancing its competitive position in the pain management market.
- Market Potential: Vertex estimates that there are 80 million acute pain patients in North America and Europe, providing both Vertex and Eli Lilly opportunities to profit in this market; although Vertex currently leads, Eli Lilly's R&D progress could shift the competitive landscape.
- Strong Financial Performance: Despite Vertex's underperformance over the past 12 months, it expects to generate at least $500 million in revenue this year from Journavx and gene-editing drug Casgevy, indicating potential in new drug launches, while Eli Lilly is also viewed as a strong investment due to its robust pipeline and profitability.
See More
Vertex and Eli Lilly Compete in Non-Opioid Pain Management Market
- Intensifying Market Competition: Vertex Pharmaceuticals leads the non-opioid pain management market with its FDA-approved Journavx, the first oral non-opioid pain signal inhibitor, which, despite currently low revenue, is expected to see significant sales growth in the coming years and may expand into diabetic peripheral neuropathy (DPN) treatment.
- Acquisition Strategy: Eli Lilly is actively entering the non-opioid pain management space through acquisitions, including SiteOne Therapeutics for up to $1 billion and 4E Therapeutics, whose lead asset 4ET1103 demonstrated a robust safety profile in phase 1 studies, indicating Lilly's potential in this market.
- Vast Market Opportunity: Vertex estimates that there are 80 million patients suffering from acute pain in North America and Europe, with several million more in niche markets like DPN, providing significant market opportunities for both Vertex and Eli Lilly; while Vertex currently holds the lead, Lilly could dominate if its products demonstrate superior efficacy.
- Strong Financial Performance: Although Vertex has lagged broader equities over the past 12 months, its dominance in the cystic fibrosis market ensures solid financial results, with expectations of at least $500 million in revenue this year from Journavx and gene editing drug Casgevy, highlighting the company's potential in new product launches.
See More
Vertex and Eli Lilly's Market Competition in Pain Management
- Market Leadership: Vertex Pharmaceuticals holds a monopoly in the cystic fibrosis (CF) drug market, while Eli Lilly excels in anti-obesity medications and diabetes care, although both companies are actively seeking to reduce their reliance on their core markets.
- Non-Opioid Drug Innovation: Vertex's Journavx became the first oral non-opioid pain signal inhibitor approved by the FDA, and while it has not generated significant revenue yet, sales are expected to ramp up over the next few years, helping the company decrease its dependence on CF products.
- Acquisition Strategy: Eli Lilly acquired SiteOne Therapeutics last year for up to $1 billion, securing the key asset STC-004, a non-opioid treatment for chronic pain, and recently announced the acquisition of 4E Therapeutics, further expanding its footprint in the non-opioid pain treatment space.
- Market Opportunity: Vertex estimates that there are 80 million patients suffering from acute pain in North America and Europe, providing both Vertex and Eli Lilly with significant profit potential in this market; despite Vertex's first-mover advantage, Eli Lilly could still dominate if its candidates demonstrate superior efficacy.
See More
ARK Invest Increases Stake in Tesla and Snowflake While Reducing Roku Holdings
- Increased Tesla Holdings: On June 18, ARK Invest acquired approximately 44,000 shares of Tesla valued at about $17.6 million, reflecting ongoing confidence in the electric vehicle market despite market fluctuations.
- Acquisition of Snowflake: The firm also purchased around 149,700 shares of Snowflake for approximately $34.8 million, indicating a bullish outlook on cloud computing and data analytics, aiming to capitalize on future growth opportunities.
- Reduced Roku Exposure: ARK Invest sold about 561,800 shares of Roku valued at approximately $77.6 million, reducing its investment in the streaming platform, which reflects a reassessment of technology stocks and portfolio adjustments.
- Healthcare Investment: Additionally, ARK increased its stake in Eli Lilly by nearly 2,400 shares worth about $2.7 million, demonstrating a focus on the healthcare sector to diversify its portfolio amid market uncertainties.
See More
Eli Lilly and Twist Leverage AI to Accelerate Drug Development
- AI Innovation at Eli Lilly: Eli Lilly is collaborating with OpenAI to accelerate drug discovery and has established an AI co-innovation lab with Nvidia, aiming to identify promising molecules faster than traditional methods, which is expected to enhance its competitive edge in drug development.
- Strong Financial Performance: In Q1 2026, Eli Lilly reported a 56% revenue increase to $19.8 billion and a 168% surge in net income to $7.4 billion, demonstrating the company's ability to achieve high growth efficiency despite its large scale, further solidifying its market position.
- Growth Potential for Twist: Twist Bioscience's revenue rose 19% to $110.7 million in Q2 of fiscal 2026, marking 13 consecutive quarters of growth; however, its net loss widened to $44 million, yet the partnership with Amazon provides significant momentum for future drug development.
- Market Outlook Analysis: Both companies showcase distinct approaches in AI-driven drug development, with Eli Lilly focusing on innovation in established drugs while Twist seeks higher-risk returns in synthetic DNA, reflecting the broad potential of AI in the pharmaceutical industry.
See More
Eli Lilly and Twist Bioscience: AI in Drug Development
- AI Innovation at Eli Lilly: Eli Lilly collaborates with OpenAI for drug discovery and establishes an AI co-innovation lab with Nvidia, aiming to accelerate drug development and enhance its position in the competitive pharmaceutical market.
- Strong Financial Performance: In Q1 2026, Eli Lilly reported a 56% revenue increase to $19.8 billion and a 168% surge in net income to $7.4 billion, indicating improved operational efficiency and promising future growth potential despite its large scale.
- Market Dynamics for Twist Bioscience: Twist Bioscience's revenue rose 19% to $110.7 million in Q2 2026, marking 13 consecutive quarters of growth, although net losses widened to $44 million, highlighting challenges faced during expansion.
- Partnership with Amazon: Twist Bioscience has become a key lab in Amazon's Bio Discovery platform, leveraging AI to design drugs and collaborate with real-world partners, which is expected to create new business growth opportunities and enhance its market competitiveness.
See More
